Literature DB >> 21153265

Prolonged stimulation by follicle-stimulating hormone is required for the induction of ovarian follicular cysts by human chorionic gonadotropin in hypophysectomized rats.

K Bogovich1.   

Abstract

Combined stimulation by follicule-stimulating hormone (FSH) and subovulatory doses of human chorionic gonadotropin (hCG, luteinizing hormone [LH]-like activity) produces large ovarian follicular cysts in hypophysectomized (HYPOXD) immature rats. To obtain a better understanding of the extent to which stimulation by FSH is required in order for hCG to induce these ovarian cysts, immature HYPOXD rats were given subcutaneous (sc) injections of 1 IU hCG twice daily for 9 d, either alone or with daily injections of 2 μg of highly purified ovine FSH on 1. Day one of hCG treatment; 2. Days one and two of hCG treatment; 3. Days one through five of hCG treatment; or 4. All 9 d of hCG treatment. Ovaries and serum samples were collected on the morning of d 10 of treatment. Animals that were treated for 9 d with hCG, but that received either no FSH or only 1 or 2 d of FSH treatment, did not display antral follicles on day 10 of treatment. The largest cross-sectional areas for the ovaries from animals that received 1 or 2 d of FSH treatments ranged between 6.84±0.51 mm(2) and 8.94±0.89 mm(2). The diameters of the largest preantral follicles in the ovaries of these two groups ranged between 0.278±0.011 and 0.320±0.028 mm, respectively. In contrast, ovaries from hCG-treated HYPOXD rats that received FSH treatments for either 5 or 9 d displayed follicular cysts by the morning of day 10. The largest cross-sectional areas for the ovaries from these two treatment groups were similar (15.68±1.61 and 18.7±5.13 mm(2), respectively), as were the mean diameters of the cystic follicles in these two groups (0.929±0.096 and 0.830±0.063 mm, respectively). Although serum androstenedione and testosterone concentrations were greater for HYPOXD rats that received combined FSH+hCG treatments than for animals that received hCG treatments alone, these concentrations did not increase with increasing numbers of days of FSH treatment. As with serum androstenedione and testosterone concentrations, serum estradiol and estrone concentrations for HYPOXD rats treated with hCG alone were limited (0.002±0.001 and 0.004±0.002 ng/mL, respectively), but had increased by day 10 after a single injection of FSH on day one of treatment. In contrast to serum androgen concentrations, serum estradiol and estrone concentrations continued to increase as the number of days of combined FSH+hCG treatment increased. These observations indicate that, in the rat, a significant period of exposure to tonic stimulation by both FSH and LH-like activity is required for the development of large ovarian cysts. Further, this period of exposure to FSH appears to be linked to increased peripheral serum estrogen concentrations, rather than to increased androgen concentrations. Therefore, the data provide indirect support for the concept that estrogens play a direct role, at the level of the ovary, in the induction of large ovarian cysts in the rat.

Entities:  

Year:  1996        PMID: 21153265     DOI: 10.1007/BF02782755

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  27 in total

1.  Hormonal regulation of granulosa cell inhibin biosynthesis.

Authors:  T A Bicsak; E M Tucker; S Cappel; J Vaughan; J Rivier; W Vale; A J Hsueh
Journal:  Endocrinology       Date:  1986-12       Impact factor: 4.736

2.  A comparison of 17 beta-hydroxysteroid oxidoreductase type 1 and type 2 activity of cytosol and microsomes from human term placenta, ovarian stroma and granulosa-luteal cells.

Authors:  C H Blomquist; D G Bealka; H C Hensleigh; G E Tagatz
Journal:  J Steroid Biochem Mol Biol       Date:  1994-06       Impact factor: 4.292

3.  Effects of human chorionic gonadotropin and progesterone on follicular development in the immature rat.

Authors:  J S Richards; K Bogovich
Journal:  Endocrinology       Date:  1982-11       Impact factor: 4.736

Review 4.  Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation.

Authors:  J S Richards
Journal:  Physiol Rev       Date:  1980-01       Impact factor: 37.312

5.  Expression of 17 beta-hydroxysteroid dehydrogenase in the rat ovary during follicular development and luteinization induced with pregnant mare serum gonadotrophin and human chorionic gonadotrophin.

Authors:  S A Ghersevich; M H Poutanen; H J Rajaniemi; R K Vihko
Journal:  J Endocrinol       Date:  1994-03       Impact factor: 4.286

6.  Insulin-like growth factor-I selectively stimulates cholesterol side-chain cleavage expression in ovarian theca-interstitial cells.

Authors:  D A Magoffin; K M Kurtz; G F Erickson
Journal:  Mol Endocrinol       Date:  1990-03

7.  Effects of a single injection of estradiol valerate on the hypothalamic arcuate nucleus and on reproductive function in the female rat.

Authors:  J R Brawer; F Naftolin; J Martin; C Sonnenschein
Journal:  Endocrinology       Date:  1978-08       Impact factor: 4.736

8.  Follicle-stimulating hormone plays a role in the induction of ovarian follicular cysts in hypophysectomized rats.

Authors:  K Bogovich
Journal:  Biol Reprod       Date:  1992-08       Impact factor: 4.285

Review 9.  Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function.

Authors:  E Y Adashi; C E Resnick; A J D'Ercole; M E Svoboda; J J Van Wyk
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

10.  A chemical approach to solving bridging phenomena in steroid radioimmunoassays.

Authors:  G D Nordblom; R Webb; R E Counsell; B G England
Journal:  Steroids       Date:  1981-08       Impact factor: 2.668

View more
  1 in total

1.  Obligatory roles for follicle-stimulating hormone (FSH), estradiol and androgens in the induction of small polyfollicular ovarian cysts in hypophysectomized immature rats.

Authors:  Katryna Bogovich
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.